Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
menstrual blood-derived mesenchymal stem cell exosomes
- Development stage
- Unknown
- Lead developer
- Creative Biolabs
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intra-arterial, Intravenous, Intperitoneal
01
Overview
Menstrual blood-derived mesenchymal stem cell exosomes (MenSC-Exos) are extracellular vesicles (EVs) secreted by mesenchymal stem cells (MSCs) isolated from human menstrual blood. These bilipid membrane vesicles, typically 30–100 nm in diameter, act as a cell-free therapeutic modality by delivering a bioactive cargo of proteins, lipids, mRNAs, and microRNAs (miRNAs) to recipient cells. MenSC-Exos have been investigated for their regenerative, anti-fibrotic, and anti-apoptotic properties in various conditions, including liver cirrhosis, premature ovarian insufficiency (POI), and diabetic wound healing. They modulate key signaling pathways such as SMAD3/AKT/MDM2/P53 and promote angiogenesis through the delivery of factors like angiopoietin-2 and angiogenin. Clinical studies have demonstrated their potential to reduce portal vein pressure and improve liver function when administered via hepatic artery infusion.
- Other names
- 宫血间充质干细胞来源外泌体Menstrual blood-derived MSC exosomes
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)ANG (Angiogenin (ribonuclease 5))ANGPT2 (Angiopoietin-2)ICAM1 (Intercellular Adhesion Molecule 1)MDM2 (Mouse double minute 2 homolog)SMAD3 (SMAD family member 3)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on menstrual blood-derived mesenchymal stem cell exosomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on menstrual blood-derived mesenchymal stem cell exosomes.